Health
Exploring Ongoing Trials With 177Lu-PSMA-617 in Prostate Cancer – Targeted Oncology
Arun Azad, MBBS, PhD, discusses ongoing studies of lutetium-177-PSMA radionuclide in patients with prostate cancer.
Arun Azad, MBBS, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne, and chair of the ANZUP Cancer Trials Group Translational, discusses ongoing studies of lutetium-177-PSMA (177Lu-PSMA-617) radionuclide in patients with prostate cancer.
Theres the UpFrontPSMA trial (NCT04343885), a randomized phase 2 study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel alone in patients with metastatic hormone-naïve prostate cancer that is recruiting right now….
-
General7 hours agoFerries and celebrities as pollies dash to win the west
-
Noosa News12 hours agoCSIRO, winemakers pair to breed mildew, climate-resistant grapevines
-
Noosa News15 hours agoSpinach salads back on supermarket shelves amid E. coli probe
-
Business17 hours ago$10,000 invested in Telstra shares at Christmas is now worth